<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109784</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-1</org_study_id>
    <nct_id>NCT01109784</nct_id>
  </id_info>
  <brief_title>Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).</brief_title>
  <official_title>Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of dual antiplatelet therapy is considered standard of care in patients post
      percutaneous coronary intervention (PCI) with stenting. However, a significant proportion of
      patients is considered clopidogrel resistant and this resistance is shown to be accompanied
      by future adverse events. Additionally, clopidogrel resistance has been linked with the
      CYP2C19 polymorphism. The hypothesis of the study is to define in consecutive patients
      undergoing PCI those that are clopidogrel resistant PCI following routinely used loading as
      estimated predischarge with the VerifyNow point of care system of platelet reactivity.
      Clopidogrel resistant patients will be randomized in 1:1 fashion to prasugrel 10 mg or
      clopidogrel 150mg daily. Platelet reactivity will be assessed at day 30, when treatment
      crossover will be performed. At day 60 platelet reactivity will be determined as well. In
      addition, in all patients genetic determination of CYP polymorphisms (including the
      CYP2C19)known to affect clopidogrel metabolism will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity Units (PRU) assessed by VerifyNow P2Y12(Accumetrics)</measure>
    <time_frame>Day 60</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prasugrel per os 10mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel per os 150mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>prasugrel 10 mg/day</description>
    <arm_group_label>prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel per os 150mg/day</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  Patients having PCI with stenting 24-48 hours prior randomization, for 1. Stable
             angina 2.Ischaemia in provocative test 3.Acute coronary syndrome (unstable angina or
             myocardial infarction)

          -  Written Informed consent

          -  Platelet reactivity units (PRU) (VerifyNow) &gt;230

        Exclusion Criteria:

          -  A history of bleeding diathesis

          -  Chronic oral anticoagulation treatment

          -  Contraindications to antiplatelet therapy

          -  Known platelet function disorders

          -  PCI or coronary artery bypass surgery &lt; 3 months

          -  Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; Thrombolysis in myocardial
             infarction flow 3)

          -  Planned staged PCI in the next 60 days

          -  Hemodynamic instability

          -  Cancer or hemodialysis

          -  Platelet count &lt;100 000/ μL, hematocrit &lt;30%

          -  Creatinine clearance &lt;25 ml/min

          -  A life expectancy&lt;1 year, inability to give informed consent

          -  High likelihood of being unavailable for the Day 60 follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department, Patras University Hospital</name>
      <address>
        <city>Rio, Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dimitrios Alexopoulos</name_title>
    <organization>Patras University Hospital</organization>
  </responsible_party>
  <keyword>coronary angioplasty</keyword>
  <keyword>clopidogrel resistance</keyword>
  <keyword>prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

